Cervical Spondylosis Treatment Market, By Type of Treatment (Medications (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Muscle relaxants, Antidepressants and Others) and Surgery), By Route of Administration (Oral, Injection, Topical, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)
The global cervical spondylosis treatment market size was valued at US$ 5.4 Billion in 2023 and is expected to reach US$ 7.9 Billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 5.6% from 2022 to 2030. The growth in the cervical spondylosis treatment market is attributed to factors such as the increasing prevalence of cervical spondylosis, rising geriatric population, and the development of innovative treatment options.
In 2023, North America dominated the cervical spondylosis treatment market in terms of revenue share, followed by Europe and Asia Pacific. The growth in the North America region is attributed to factors such as the high prevalence of cervical spondylosis, the availability of advanced healthcare infrastructure, and the presence of key market players. It is estimated to hold around 36.7% of the global market share. For instance, according to the StatPearls journal, in May 2023, cervical spondylosis was considered a natural process of aging with a 95% prevalence by the age of 65 years in the U.S. Most people remain asymptomatic but can suffer from axial neck pain, as well as with cervical radiculopathy and/or cervical myelopathy.
Europe is also a significant market for cervical spondylosis treatment, owing to the high prevalence of cervical spondylosis in the region and the availability of advanced healthcare infrastructure. The growing geriatric population in the region is also driving the demand for cervical spondylosis treatment. Europe is estimated to hold approximately 30.7% of the global market share.
Asia Pacific is expected to witness significant growth in the cervical spondylosis treatment market during the forecast period owing to factors such as the increasing prevalence of cervical spondylosis, the growing geriatric population, and the development of healthcare infrastructure in emerging economies. The market in the Asia Pacific region is estimated to capture around 25.2% of the global market share.
Figure 1. Global Cervical Spondylosis Treatment Market Share (%), By Region, 2023
The global cervical spondylosis treatment market is expected to grow steadily driven by the rising geriatric population worldwide and the increasing prevalence of neck pain and musculoskeletal disorders. Asia Pacific is likely to emerge as the fastest growing region owing to a huge patient population and improving healthcare infrastructure in developing countries such as China and India. North America will continue dominating the market supported by advanced medical technologies and strong reimbursement framework for cervical spondylosis patients.
Cervical Spondylosis Treatment Market Drivers:
Increasing prevalence of cervical spondylosis: The growing prevalence of cervical spondylosis, especially among the elderly population, is driving the demand for cervical spondylosis treatment. This is attributed to factors such as sedentary lifestyle, poor posture, and degeneration of spinal discs. For instance, according to Indian Journal of Applied Research, in June 2017, about 10 million persons per year were affected by cervical spondylosis in India alone. The incidence of neck pain in adults is 25-50% than that of children per year. It is the most common spine dysfunction in elderly people.
Growing geriatric population: The growing geriatric population, especially in developed economies, is driving the demand for cervical spondylosis treatment. Elderly individuals are more prone to cervical spondylosis, which can lead to reduced quality of life and functional impairment.
Advancements in healthcare infrastructure: The advancements in healthcare infrastructure, especially in emerging economies, is driving the demand for cervical spondylosis treatment. This includes the development of advanced diagnostic tools, treatment technologies, and rehabilitation services. For instance, according to the Biomolecules & Biomedicine journal, in April 2023, researchers at Guangxi Normal University, China evaluated the effectiveness of therapies including Sling Exercises Training (SET), fascia manipulation, Muscle Energy Technique (MET), and Proprioceptive Neuromuscular Facilitation (PNF) with combination with virtual reality technology that aid the rehabilitation of cervical spondylosis. It was found that the combination of VR technology and other novel technologies has the potential to improve the field of pain management.
Increasing healthcare expenditure: The increasing healthcare expenditure, especially in developed economies, is driving the demand for cervical spondylosis treatment. Governments and private entities are investing more in healthcare, which is leading to improved access to treatment options for patients.
Development of personalized treatment options: The trend towards personalized medicine presents an opportunity to develop customized cervical spondylosis treatment options that are tailored to the specific needs and preferences of patients. This can include the use of different treatment modalities, rehabilitation techniques, and follow-up care.
Expansion into emerging markets: The cervical spondylosis treatment market has significant potential for growth in emerging markets, where the prevalence of the condition is increasing. There is an opportunity to expand into these markets and offer innovative treatment options that meet the specific needs and preferences of patients in these regions. For instance, according to the BMC Musculoskeletal Disorders journal, in 2018, an epidemiological study of cervical spondylosis was conducted in the Chinese population. The prevalence of cervical spondylosis was 13.76%, which was higher than the prevalence of diabetes (9.7%). Approximately 2.7 million patients suffered from cervical spondylosis in Beijing, a city having a population of 20 million.
Technological advancements: The development of advanced technologies, such as robotics and virtual reality, presents an opportunity to enhance the effectiveness and efficiency of cervical spondylosis treatment. These technologies can offer improved outcomes, reduced healthcare costs, and enhanced patient experience.
Focus on patient education and awareness: The lack of awareness and understanding about cervical spondylosis among patients and healthcare providers presents an opportunity to focus on patient education and awareness initiatives. This can include the development of educational materials, public health campaigns, and training programs for healthcare professionals.
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa
Segments covered:
By Type of Treatment: Medications (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Muscle relaxants, Antidepressants and Others) and Surgery
By Route of Administration: Oral, Injection, Topical, and Others
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
Growing adoption of minimally invasive procedures: The trend towards minimally invasive procedures, such as endoscopic surgery and percutaneous disc decompression, is driving the demand for cervical spondylosis treatment. These procedures offer reduced pain, faster recovery times, and improved outcomes, compared to traditional open surgery.
Increasing use of non-surgical interventions: The increasing use of non-surgical interventions, such as physical therapy, medication, and acupuncture, is driving the demand for cervical spondylosis treatment. These interventions offer a less invasive and more conservative approach to treating cervical spondylosis. For instance, in April 2023, according to Kerala Ayurveda, an organization based in India, Ayurveda uses medicines and Panchakarma therapies like medicated enema or Basti that may improve the symptoms of cervical spondylosis. These procedures may run depending on how well your body responds to the treatment. Few treatments that are recommended and administered by certified Ayurveda practitioners include Abhyanga Swedam, Elakizhi, Sarvangadhara, Greeva/Kati Vasti, and others.
Focus on patient-centered care: The trend towards patient-centered care is driving the demand for cervical spondylosis treatment that is tailored to the specific needs and preferences of patients. This includes the use of personalized treatment plans, rehabilitation programs, and follow-up care that aim to improve patient outcomes and quality of life.
Increasing use of advanced imaging technologies: The increasing use of advanced imaging technologies, such as MRI and CT scans, is driving the demand for cervical spondylosis treatment. These technologies can provide a more accurate diagnosis and enable healthcare providers to develop more effective treatment plans.
Cervical Spondylosis Treatment Market Restraints:
High treatment costs: The high cost of cervical spondylosis treatment, especially for surgical interventions, can limit access to treatment for some patients. This can result in delayed diagnosis and treatment, which can lead to more severe symptoms and reduced quality of life. For instance, according to Vaidam Health, a medical travel assistant company, cervical spondylosis treatment cost in India for Indian patients is between US$ 5,300 to US$ 7,110. The cost for international patients is between US$ 9,000 to US$ 11,000. Patient has to stay in the hospital for 5 days and outside the hospital for 10 days. The total cost of the treatment depends on the diagnosis and facilities opted by the patient.
Limited reimbursement policies: The limited reimbursement policies for cervical spondylosis treatment can limit access to treatment for some patients. This can result in reduced adoption of innovative treatment options and slower market growth.
Limited availability of healthcare infrastructure: The limited availability of healthcare infrastructure, especially in rural and underserved areas, can limit access to cervical spondylosis treatment. This can result in delayed diagnosis and treatment, which can lead to more severe symptoms and reduced quality of life.
Recent Developments
New product launches/approvals
In September 2023, ZimVie Inc., a global life sciences leader in the dental and spine markets, announced that the U.S. Food and Drug Administration (FDA) approved its Mobi-C Cervical Disc Hybrid Investigational Device Exemption (IDE) application. The decision authorizes ZimVie to begin enrolling U.S. patients in the study, which will follow patients who receive simultaneous Cervical Disc Arthroplasty (CDA) and Anterior Cervical Discectomy and Fusion (ACDF) at adjacent levels between C3 and C7.
In February 2019, Orthofix Medical Inc., a global medical device company focused on musculoskeletal products and therapies, announced the U.S. Food and Drug Administration (FDA) approval of the M6-C artificial cervical disc for patients suffering from cervical disc degeneration
Acquisition and partnerships
In 2020, Stryker, a global medical technology company, announced the acquisition of Wright Medical Group N.V., a leading provider of orthopedic medical devices. This acquisition expanded Stryker's product portfolio and expertise in the spinal surgery market including the treatment of cervical spondylosis.
In 2021, the American Association of Neurological Surgeons (AANS) and the American Academy of Orthopaedic Surgeons (AAOS) announced that Medtronic, a global leader in medical technology, has become the latest industrial sponsor of the American Spine Registry. With the same objective of enhancing patient care, Medtronic's sponsorship of the ASR expands on its dedication to developing the science of spine care and enhancing the results of spine surgery.
In August 2023, ZimVie Inc., a global life sciences company in the dental and spine markets, announced that it has expanded its collaboration agreement with Brainlab, a spine imaging, planning, and navigation portfolio leader with robotic imaging, surgical assistance, and mixed reality to support spinal surgeries
Top Companies in the Cervical Spondylosis Treatment Market
Pfizer Inc.
Abbott Laboratories
AstraZeneca Plc.
Novartis AG
Merck & Co. Inc.
Teva Pharmaceutical Industries Ltd.
Amgen Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
GlaxoSmithKline plc
Johnson & Johnson Services, Inc.
Sanofi S.A.
Stryker Corporation
Zimmer Biomet Holdings, Inc.
Medtronic plc
*Definition: Cervical spondylosis treatment refers to the various approaches and interventions aimed at managing the symptoms and reducing the impact of cervical spondylosis, a degenerative condition affecting the cervical spine (neck region). Cervical spondylosis is characterized by wear and tear, as well as age-related changes, in the discs and joints of the cervical spine.
Share
About Author
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
The global Cervical Spondylosis Treatment Market size was valued at USD 5.4 billion in 2023 and is expected to reach USD 7.9 billion in 2030.
The global cervical spondylosis treatment market is estimated to be valued at US$ 5.4 Bn in 2023, and is expected to exhibit a CAGR of 5.6% between 2023 and 2030.
Increasing prevalence of cervical spondylosis and growing geriatric population are expected to drive the market growth.
Medications is the leading treatment type segment in the market.
High treatment costs and limited reimbursement policies are expected to hinder the global cervical spondylosis treatment market growth over the forecast period.
The major players operating in the market are Pfizer Inc., Abbott Laboratories, AstraZeneca Plc., Novartis AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Sanofi S.A., Stryker Corporation, Zimmer Biomet Holdings, Inc., and Medtronic plc.
U.S.: 
U.K. : 
India : 
